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Background Secretion of adrenomedullin (ADM) is stimulated by volume overload to maintain endothelial barrier function,
and higher levels of biologically active (bio-) ADM in heart failure (HF) are a counteracting response to vascular
leakage and tissue oedema. This study aimed to establish the value of plasma bio-ADM as a marker of congestion
in patients with worsening HF.
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Methods
and results
The association of plasma bio-ADM with clinical markers of congestion, as well as its prognostic value was studied
in 2179 patients with new-onset or worsening HF enrolled in BIOSTAT-CHF. Data were validated in a separate
cohort of 1703 patients. Patients with higher plasma bio-ADM levels were older, had more severe HF and more
signs and symptoms of congestion (all P< 0.001). Amongst 20 biomarkers, bio-ADM was the strongest predictor of
a clinical congestion score (r2 = 0.198). In multivariable regression analysis, higher bio-ADM was associated with
higher body mass index, more oedema, and higher fibroblast growth factor 23. In hierarchical cluster analysis,
bio-ADM clustered with oedema, orthopnoea, rales, hepatomegaly and jugular venous pressure. Higher bio-ADMwas
independently associated with impaired up-titration of angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers after 3months, but not of beta-blockers. Higher bio-ADM levels were independently associated with an
increased risk of all-cause mortality and HF hospitalization (hazard ratio 1.16, 95% confidence interval 1.06–1.27,
P= 0.002, per log increase). Analyses in the validation cohort yielded comparable findings.
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Conclusions Plasma bio-ADM in patients with new-onset and worsening HF is associated with more severe HF and more oedema,
orthopnoea, hepatomegaly and jugular venous pressure. We therefore postulate bio-ADM as a congestion marker,
which might become useful to guide decongestive therapy.
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Introduction
Pulmonary and systemic congestion play a major role in symptoms
that are associated with worsening heart failure (HF).1,2 Conse-
quently, patients who are hospitalized for worsening HF with a
poor diuretic response and incomplete decongestion at discharge
have a higher risk of death and hospital re-admission.3,4 There-
fore, an easy-to-use surrogate biomarker for the assessment of a
patient’s congestion status might be of great clinical value.
A promising novel biomarker in this context is the biologi-
cally active form of adrenomedullin (bio-ADM), a 52-amino acid
ringed, vasodilatory peptide hormone that is elevated in acute and
chronic HF.5–8 The adrenomedullin (ADM) gene encodes a pre-
prohormone, which after cleavage generates a pro-ADM peptide,
which by proteolytic fragmentation becomes a glycine-extended,
inactive ADM. This is enzymatically converted to bio-ADM. Secre-
tion of ADM has been demonstrated from endothelial cells, car-
diac myocytes, vascular smooth muscle cells, and leucocytes. ADM
is cleared by neutral endopeptidase and through binding with its
receptors. The most dominant role of ADM is thought to be the
regulation of endothelial function, and ADM has been shown to
play an essential role in maintaining endothelial barrier function
and disruption hereof results in vascular leakage, and systemic
and pulmonary oedema.9,10 ADM expression is stimulated by vol-
ume overload, and increased plasma ADM reflects excessive fluid
overload.11 In a recent study in patients with acute HF, bio-ADM at
baseline was associated with more signs of congestion and higher
bio-ADM levels after 7 days of decongestive treatment were asso-
ciated with significant residual congestion at this time point.7 The
findings from this study suggest that bio-ADM might be a potential
marker of congestion both at admission and during/after a hospi-
talization for acute HF. In the current study, we aimed to further
evaluate clinical and biological factors associated with bio-ADM in
patients with worsening and new-onset HF, and assess associations
with congestion and outcome, in order to gain greater insight into
the potential role of bio-ADM in HF.
Methods
Study population
We studied plasma bio-ADM in patients enrolled in ‘A systems
BIOlogy Study to TAilored Treatment in Chronic Heart Failure’
(BIOSTAT-CHF), a multicentre, multinational, prospective obser-
vational study. In the BIOSTAT-CHF index cohort, 2516 patients
were enrolled with worsening signs and/or symptoms of HF from 11
European countries, who were on suboptimal guideline-recommended
medical therapy [i.e. ≤ 50% of target doses of angiotensin-converting
enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB)
and beta-blockers]. Patients could be enrolled as in- and outpatients,
however the majority of patients were hospitalized for worsening HF.
A number of patients were admitted or presented to the hospital
for other reasons, yet developed worsening or new-onset HF dur-
ing hospitalization. The most frequent other reasons were rhythm
disturbances, acute coronary syndrome, implantation of a device,
or up-titration of HF medication. Patients should have objective
evidence of cardiac dysfunction documented by either left ventricular ..
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.. ejection fraction ≤ 40% or a B-type natriuretic peptide (BNP) level
≥ 400 pg/mL or N-terminal pro BNP (NT-proBNP) ≥ 2000 pg/mL
during screening. During the first 3months after enrolment, investi-
gators were expected to optimize treatment of HF with ACEi/ARB
and beta-blockers, according to the doses indicated in the 2012
European Society of Cardiology guidelines.12
The results were subsequently validated in the BIOSTAT-CHF valida-
tion cohort, in which 1738 patients were recruited from six centres in
Scotland, United Kingdom. In summary, in- and outpatients diagnosed
with HF with a previous admission for HF and maintenance dose of
≥ 20mg of furosemide per day were eligible for enrolment. Details on
both cohorts have been previously published.13–16
All patients provided written informed consent to participate in
the study and BIOSTAT-CHF was conducted in concordance with the
Declaration of Helsinki. The study was also approved by national and
local ethics committees.
Study assessments
Plasma bio-ADM was measured at baseline in 2179 patients in the
index cohort and in 1703 patients in the validation cohort, using
an immunoassay (sphingotest® bio-ADM®) developed by sphingotec
GmbH (Hennigsdorf, Germany).8,17 Included patients were generally
comparable to excluded patients for both cohorts (online supple-
mentary Tables S1 and S2). In brief, the bio-ADM immunoassay is a
one-step sandwich chemiluminescence immunoassay based on acri-
dinium NHS-ester labelling for the detection of human ADM in unpro-
cessed, neat plasma. It uses two mouse monoclonal antibodies, one
directed against the mid-region and the other directed against the ami-
dated C-terminal moiety of ADM. The assay uses 50𝜇L of plasma
samples/calibrators and 220𝜇L of labelled detection antibody. Upon
storage at room temperature, bio-ADM in EDTA plasma is stable for up
to 24 h, and samples are unaffected by at least up to four freeze–thaw
cycles. The analytical assay sensitivity is 2 pg/mL. The lower detection
limit is 3 pg/mL, and intra- and interassay coefficients were 5–10%, and
4–8%, respectively, in the above normal measuring range. This assay is
highly specific to bio-ADM as it only reacts with the mature amidated
C-terminus of ADM, and not to other variants of (pro-) ADM.17 In
healthy subjects, median bio-ADM concentration was 20.7 pg/mL (99th
percentile: 43 pg/mL).18
A great number of other biomarkers from multiple pathophysiologi-
cal domains, including markers of inflammation, apoptosis, remodelling,
myocyte stress, angiogenesis, endothelial function and renal function
were measured. Pro-enkephalin (PENK) was measured using a
sandwich immunoassay (sphingotest® penKid®) targeting PENK A
amino acids 119–159 developed by sphingotec GmbH (Hennigsdorf,
Germany). Pro-ADM was measured using a sandwich ELISA on a
Luminex® platform (Alere Inc., San Diego, CA, USA). Interleukin-6
and endothelin-1 were measured in frozen plasma by Singulex Inc.
(Alameda, CA, USA) using high-sensitive single molecule counting
(SMC™) technology (RUO, Erenna® Immunoassay System, Singulex
Inc., Alameda, CA, USA). NT-proBNP was measured using electro-
chemiluminescence on a Cobas e411 analyser, using standard methods
(Roche Diagnostics GmbH, Mannheim, Germany). Measurement of
other biomarkers was performed as previously described.15,19 From all
available biomarkers, 20 were selected for these analyses based on their
known involvement in volume overload, neurohormonal activation,
renal function, and outcome (online supplementary Table S3).
A congestion score was calculated as the sum of peripheral oedema
depending on the extent (0 to 1/3 to 2/3 to 1), jugular venous pressure
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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(JVP) (0 to 1), and orthopnoea (0 to 1) for the index cohort. For the
validation cohort, the maximum score is 2, as orthopnoea was not
routinely collected in this cohort. A modified congestion score, where
oedema was scored 1 point if oedema extended above the knee, was
used in a sensitivity analysis to balance the impact of oedema on the
congestion score.
Outcomes
The endpoints selected for these analyses were all-cause mortal-
ity, cardiovascular mortality, and the combined endpoint of all-cause
mortality or first occurrence of HF hospitalization. Cardiovascular
mortality was based on the narrative provided for each death by a
small committee of cardiologists. Additionally, the association between
bio-ADM and therapy optimization for ACEi/ARB and beta-blockers
at 3months was evaluated.
Statistical analysis
Baseline clinical variables and biomarkers were evaluated over
tertiles of bio-ADM levels. Frequency (percentage) was used
to summarize categorical variables while normally distributed con-
tinuous variables were summarized with mean± standard deviations
and non-normally distributed continuous variables with median
[interquartile range]. Trends over tertiles of bio-ADM were statisti-
cally tested with Cochran–Armitage trend test, Jonckheere–Terpstra,
or a linear regression model for categorical variables, non-normally
distributed continuous variables, and normally distributed continu-
ous variables, respectively. Uni- and multivariable linear regression
analysis was performed with log transformed bio-ADM as a depen-
dent variable. Transformations were checked using multifractional
polynomials. Multivariable linear regression analysis, including all
variables with P< 0.10 in univariable analysis, were constructed via
backward elimination and validated using bootstrap re-sampling with
1000 replicates. The model was tested for collinearity and checked
by plotting residuals. The correlation heat maps and dendrograms
were constructed using the ggplot2, reshape2, fastcluster, Hmisc, and
sparcl packages in R. Cox proportional hazards regression analysis was
performed to examine associations with clinical outcomes. Bio-ADM
was investigated as a continuous variable and by quintiles. Multivariable
models were adjusted for an outcome model specifically developed
and validated in the BIOSTAT-CHF index and validation cohort.14 The
added value of bio-ADM for estimating the risk of poor outcome was
assessed by examining gain in Harrell’s C-index (a measure of model
discrimination, higher values are better), using likelihood ratio tests
for nested survival models, and assessment of continuous net reclas-
sification improvement (a category-independent measure quantifying
the degree of improvement in model-based risk estimates obtained
by adding a marker to a model). Logistic regression was used to
investigate the association between bio-ADM and ACEi/ARB use, and
whether target dose was reached. A two-tailed P-value of <0.05 was
considered statistically significant. All analyses were performed using
R: A Language and Environment for Statistical Computing, version
3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
Median bio-ADM at baseline was 33.8 [22.6–53.9] pg/mL. Baseline
characteristics over tertiles of bio-ADM are presented in Table 1. ..
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.. Patients with higher bio-ADM levels were older, had a higher
body mass index (BMI), and more severe HF (higher New York
Heart Association class, higher NT-proBNP levels, and more fre-
quently a previous HF hospitalization) (all P< 0.006). Addition-
ally, higher bio-ADM levels were associated with the presence
of signs and symptoms of congestion, lower systolic and dias-
tolic blood pressure, poorer renal function, and higher levels of
biomarkers such as fibroblast growth factor 23 (FGF23), PENK,
and interleukin-6 (all P< 0.009). Interestingly, patients with higher
bio-ADM levels used higher doses of diuretics (P< 0.001). After
9months, patients in the highest tertile were more likely to
use loop diuretics (98.2% vs. 92.2%, P= 0.018 for first vs. third
tertile), and used slightly higher doses (40 [40–50] mg vs. 60
[40–125] mg of furosemide or equivalent, P< 0.001 for first vs.
third tertile).
Association between bio-adrenomedullin
and clinical variables
The result of multivariable linear regression analysis for log
bio-ADM is shown in the online supplementary Table S4. The
strongest associations with higher log bio-ADM were higher BMI,
higher log FGF23, more frequent oedema, higher interleukin-6
and endothelin-1 (r2 = 0.580). Log pro-ADM was significantly
associated with log bio-ADM levels, yet explained only 30% of
the variance of log bio-ADM. Pro-ADM was not significant in
a multivariable model for bio-ADM; forcing this variable into
the multivariable model increased the r2 significantly to 0.594
(P< 0.001).
Correlation and network analysis
The results of hierarchical clustering of variables and a correlation
heat map are presented in Figures 1 and 2. The heat map (Figure 1)
illustrates that bio-ADM levels are most strongly correlated with
FGF23 (Spearman’s rho: 0.57, P< 0.001), pro-ADM (Spearman’s
rho: 0.54, P< 0.001), growth differentiation factor 15 (GDF15)
(Spearman’s rho: 0.49, P< 0.001), and the presence of oedema
(Spearman’s rho: 0.43, P< 0.001). In a hierarchical cluster analysis
(Figure 2), bio-ADM clustered with oedema, as well as orthopnoea,
rales, hepatomegaly and JVP – all signs of congestion. Interestingly,
pro-ADM did not cluster with bio-ADM, yet clustered with FGF23,
GDF15, and NT-proBNP.
Bio-adrenomedullin and congestion
Amongst 20 markers, bio-ADM was the strongest variable associ-
ated with a higher clinical congestion score (r2 = 0.198, P< 0.001),
compared with for instance pro-ADM (r2 = 0.120, P< 0.001),
and NT-proBNP (r2 = 0.114, P< 0.001). The modified conges-
tion score yielded similar findings. This was also observed for
the presence of oedema where bio-ADM had an area under the
curve of 0.768, compared to 0.658 for pro-ADM, and 0.641 for
NT-proBNP. Other signs and symptoms of congestion such as JVP
and orthopnoea yielded comparable findings. Table 2 shows the
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics over tertiles of bio-adrenomedullin in the index cohort
Tertile 1 Tertile 2 Tertile 3 P-value for trend
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients (n) 719 719 741
Bio-ADM (pg/mL) 19.2 [15.1–22.5] 33.3 [29.1–38.1] 67.2 [53.2–100.6]
Demographics
Male sex (%, n) 76.1 (547) 72.6 (522) 70.9 (525) 0.024
Age (years) 66.9±12.5 69.4±11.7 70.4±11.7 <0.001
Caucasian race (%, n) 98.9 (711) 98.7 (710) 99.1 (734) 0.756
BMI (kg/m2) 25.8± 4.3 27.8± 5 29.9± 6.3 <0.001
Weight (kg) 76.1±15.6 81.3± 16.7 87.7± 21 <0.001
Height (kg) 171.3± 9.4 170.8± 9.2 170.9± 9.1 0.402
NYHA class (%, n) <0.001
I 3.2 (23) 2.9 (21) 0.1 (1)
II 47.4 (341) 38.4 (276) 20.4 (151)
III 40.3 (290) 45.1 (324) 57.1 (423)
IV 6.5 (47) 11.1 (80) 18.9 (140)
LVEF (%) 30.5± 9.4 31±10.7 31.9± 12.2 0.015
HFpEF (%, n) 5.1 (35) 8.3 (53) 10.3 (65) <0.001
Clinical profile
Oedema (%, n) 10.7 (60) 22.7 (131) 52.4 (349) <0.001
Orthopnoea (%, n) 23.8 (171) 31.8 (228) 48.2 (356) <0.001
Rales> 1/3 up lung fields (%, n) 16.8 (48) 19.6 (76) 22 (103) 0.084
Jugular venous pressure (%, n) 21.1 (103) 31.5 (156) 49.4 (239) <0.001
Hepatomegaly (%, n) 8.5 (61) 12.8 (92) 20.8 (154) <0.001
Third heart tone (%, n) 10.6 (76) 8 (57) 11.1 (82) 0.731
Clinical congestion score 0 [0–1] 0.67 [0–1.33] 1.67 [0.67–2.33] <0.001
Systolic blood pressure (mmHg) 125.6± 22.2 125.4± 21.9 122.5± 21.9 0.008
Diastolic blood pressure (mmHg) 76.1±12.8 75±13.8 72.9±13.1 <0.001
Heart rate (b.p.m.) 77± 17.7 80.5± 20.6 82.6±19.9 <0.001
Hospitalization (%, n)
Type of visit <0.001
Scheduled outpatient clinic 33.9 (244) 25.5 (183) 14.3 (106)
Unscheduled outpatient clinic 6 (43) 3.9 (28) 3.6 (27)
Inpatient hospitalization 60.1 (432) 70.7 (508) 82.1 (608)
Reason for visit <0.001
Worsening HF 45.1 (324) 51.9 (373) 63.8 (473)
New-onset HF 30.6 (220) 30.5 (219) 26.5 (196)
Other 24.3 (175) 17.7 (127) 9.7 (72)
Diuretics i.v. 98.7 (310) 97.1 (372) 98.6 (545) 0.918
Inotropes i.v. 10.9 (34) 8.9 (34) 13.2 (73) 0.195
Nitrates i.v. 26.8 (83) 23.2 (89) 17.2 (95) 0.001
Heart failure history
Years since first diagnosis 0.4 [0.1–1.3] 3 [0.3–8.8] 3.7 [0.7–7.2] 0.026
Ischaemic heart disease 56.2 (357) 62.6 (402) 61.6 (405) 0.048
Hypertension 54.2 (371) 59.7 (410) 54.9 (389) 0.785
Cardiomyopathy 52.8 (349) 38.7 (251) 38.7 (259) <0.001
Valvular heart disease 37.1 (251) 40.5 (277) 44.4 (310) 0.006
NYHA class prior to decompensation/worsening HF <0.001
I 11 (79) 8.5 (61) 6.1 (45)
II 51.6 (371) 46.6 (335) 40.4 (299)
III 24.3 (175) 27.7 (199) 33.7 (250)
IV 1.9 (14) 4 (29) 4.5 (33)
Previous HF hospitalization 28.4 (204) 29.9 (215) 35.1 (260) 0.005
Medical history (%, n)
Hypertension 58.3 (419) 65.1 (468) 62.6 (464) 0.091
Atrial fibrillation 33.4 (240) 46.2 (332) 57.2 (424) <0.001
Coronary artery disease 38.1 (274) 46.5 (334) 47.1 (349) 0.001
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Continued
Tertile 1 Tertile 2 Tertile 3 P-value for trend
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Myocardial infarction 32.8 (236) 39.5 (284) 38.3 (284) 0.031
PCI 19.1 (137) 22 (158) 21.1 (156) 0.351
CABG 11.7 (84) 17.5 (126) 21.7 (161) <0.001
Pacemaker 5.7 (41) 9.5 (68) 7.2 (53) 0.301
ICD 5.7 (41) 7.5 (54) 10.4 (77) 0.001
Biventricular pacer (CRT) 1.3 (9) 1.3 (9) 3 (22) 0.014
Biventricular pacer (CRT) and ICD 5.4 (39) 6.1 (44) 8.6 (64) 0.014
Diabetes mellitus 23.5 (169) 31.6 (227) 41.4 (307) <0.001
COPD 13.1 (94) 18.2 (131) 20.2 (150) <0.001
Peripheral artery disease 7.5 (54) 12.5 (90) 13.6 (101) <0.001
Stroke 8.1 (58) 9.9 (71) 10.4 (77) 0.130
Medication
ACEi or ARB (%, n) 78 (561) 73.2 (526) 64.2 (476) <0.001
Target dose (%, n) 14.9 (107) 12.4 (89) 10.9 (81) 0.024
Beta-blockers (%, n) 85.1 (612) 83.9 (603) 80.4 (596) 0.017
Target dose (%, n) 4 (29) 6.3 (45) 6.3 (47) 0.055
Loop diuretics (%, n) 99.3 (714) 99.6 (716) 99.6 (738) 0.436
Loop diuretic dose (mg furosemide) 40 [40–62] 40 [40–80] 80 [40–150] <0.001
Aldosterone antagonists (%, n) 53.5 (385) 53.1 (382) 50.6 (375) 0.259
Digoxin (%, n) 16 (115) 18.9 (136) 20 (148) 0.050
Laboratory
Haemoglobin (g/dL) 13.7 [12.4–14.8] 13.4 [12.1–14.5] 12.7 [11.4–14] <0.001
Creatinine (𝜇mol/L) 90.2 [76.9–112] 103.8 [87–125.6] 116 [93–153] 0.708
Urea (mmol/L) 9.3 [6.7–14.7] 10.8 [7.5–17.4] 13.5 [8.8–23.8] <0.001
eGFR (mL/min/1.73m2) 71.1 [53.6–86] 58.6 [44.8–75.5] 49.7 [34.7–67.1] <0.001
Sodium (mmol/L) 140 [138–142] 140 [137–142] 139 [136–141] <0.001
Potassium (mmol/L) 4.3 [4–4.6] 4.2 [3.9–4.6] 4.2 [3.8–4.6] 0.003
Calcium (mmol/L) 1.8 [1.5–2.1] 1.8 [1.5–2] 1.7 [1.4–2] <0.001
Phosphate (mmol/L) 0.9 [0.7–1] 0.8 [0.7–1] 0.8 [0.7–1] 0.611
Albumin (g/L) 34 [29–39] 32 [28–37] 31 [25–35] <0.001
Iron (μmol/L) 10 [6–14] 8.5 [6–12] 6 [4–10] <0.001
Ferritin (μg/L) 116 [53.2–204.8] 106 [51.5–192] 81 [44–165] 0.057
Transferrin (g/L) 2 [1.6–2.4] 2 [1.6–2.4] 2 [1.5–2.5] 0.890
Aldosterone (pg/mL) 94 [43–187] 93 [44.5–180] 90 [42–211] 0.002
Renin (IU/mL) 68 [23.9–191.7] 89.1 [27.6–229] 125.1 [36.2–374.5] <0.001
NGAL (ng/mL) 50.8 [33.0–80.2] 57.8 [35.7–88.3] 76.3 [45.6–125.4] <0.001
Interleukin-6 (pg/mL) 3.4 [1.9–6.3] 4.9 [2.7–8.8] 8.6 [4.9–17] <0.001
Troponin I (ng/L) 10.4 [5.9–22.8] 12.4 [6.6–27.7] 16.3 [9–33.2] 0.785
Endothelin-1 (pg/mL) 4.5 [3.5–5.8] 5 [4–6.7] 6.7 [5.1–9] <0.001
FGF23 (RU/mL) 132.3 [90.7–217.5] 201.9 [121.9–401.1] 621.9 [274.6–1745.6] <0.001
Galectin-3 (ng/mL) 17.6 [13.0–25.0] 20.3 [15.5–28.0] 26.0 [18.8–36.7] <0.001
Pro-enkephalin (pmol/L) 73.7 [56.1–97.6] 85.1 [64.5–116.4] 105 [77.2–151.1] <0.001
Pro-ADM (ng/mL) 0.4 [0.2–0.5] 0.5 [0.3–0.7] 0.8 [0.5–1.3] <0.001
NT-proBNP (pg/mL) 1826 [825–3959] 2563.5 [1142–5101.8] 4313 [2067–9355.5] <0.001
GDF15 (pg/mL) 1974 [1306–2912] 2573 [1723.2–3980.2] 4324 [2694–7366] <0.001
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Bio-ADM, biologically active adrenomedullin; BMI, body mass index; CABG, coronary
artery bypass graft; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; FGF23, fibroblast
growth factor 23; GDF15, growth differentiation factor 15; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; ICD, implantable cardioverter defibrillator;
LVEF, left ventricular ejection fraction; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart
Association; PCI, percutaneous coronary intervention; PENK, pro-enkephalin, Pro-ADM, pro-adrenomedullin.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Biomarker position of bio-adrenomedullin depicted in a correlation heat map. Bio-ADM, biologically active adrenomedullin; BMI,
body mass index; DBP, diastolic blood pressure; FGF23, fibroblast growth factor 23; GDF15, growth differentiation factor 15; GFR, glomerular
filtration rate; HR, heart rate; JVP, jugular venous pressure; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro
B-type natriuretic peptide; PENK, pro-enkephalin; Pro-ADM, pro-adrenomedullin; SBP, systolic blood pressure.
comparison between associations of bio-ADM and NT-proBNP
with clinical markers of congestion. In particular, the associa-
tion between bio-ADM and oedema was stronger than the asso-
ciation between NT-proBNP and oedema. The distribution of
bio-ADM over quartiles of NT-proBNP (for both cohorts) is plot-
ted in the online supplementary Figure S1. Using receiver operating
characteristic (ROC) analysis, the best cut-off value of bio-ADM
to assess congestion (defined as a congestion score >1) was
34 pg/mL. ..
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..
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..
..
..
.. Bio-adrenomedullin and therapy
optimization
Higher levels of log bio-ADM were associated with lower
rates of ACEi/ARB and beta-blocker use at baseline (Table 1).
Also, patients with higher bio-ADM levels less frequently used
guideline-recommended doses of ACEi/ARB and beta-blockers
(Table 1). Furthermore, higher bio-ADM levels were inversely
associated with ACEi/ARB use and dosage after 3months of
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Biomarker position of bio-adrenomedullin depicted
in hierarchical cluster analysis. Bio-ADM, biologically active
adrenomedullin; BMI, body mass index; DBP, diastolic blood
pressure; FGF23, fibroblast growth factor 23; GDF15, growth
differentiation factor 15; GFR, glomerular filtration rate; HR,
heart rate; JVP, jugular venous pressure; NGAL, neutrophil
gelatinase-associated lipocalin; NT-proBNP, N-terminal pro
B-type natriuretic peptide; PENK, pro-enkephalin; Pro-ADM,
pro-adrenomedullin; SBP, systolic blood pressure.
up-titration (Table 3). This association remained significant after
adjustment for BMI, FGF23, PENK, NT-proBNP, estimated
glomerular filtration rate, age, sex, oedema and ACEi/ARB or
beta-blocker use at baseline. In contrast, there was no significant
independent association between bio-ADM levels and beta-blocker
dosage after 3months of up-titration.
Bio-adrenomedullin and outcomes
During a median follow-up of 21 [15–27] months, 583 (26.7%)
patients died and 914 (41.9%) patients experienced the combined
endpoint of all-cause mortality or HF hospitalization. In univariable
Cox regression analysis, log bio-ADM was significantly associated
with an increased risk of all-cause mortality [hazard ratio (HR)
1.79, 95% confidence interval (CI) 1.63–1.97; P< 0.001 per log
increase], and the combined endpoint (HR 1.71, 95%CI 1.58–1.85;
P< 0.001 per log increase). This remained significant for both end-
points after adjustment for the BIOSTAT-CHF risk model (Table 4),
as well as after adjustment for the BIOSTAT-CHF risk model with .
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.. addition of NT-proBNP and the clinical congestion score (HR
1.19, 95% CI 1.03–1.36; P= 0.015 per log increase for the com-
bined endpoint). The association of bio-ADM with outcome was
also analysed over quintiles of bio-ADM, where after multivari-
able adjustment quintile 4 and 5, i.e. the highest bio-ADM levels,
remained significantly associated with an increased risk of adverse
outcome (Table 3). Kaplan–Meier curves for all-cause mortality per
quintile of bio-ADM are shown in Figure 3, illustrating a higher risk
over increasing quintiles of bio-ADM (log-rank P< 0.001). Higher
levels of bio-ADMwere independently associated with an increased
risk of cardiovascular mortality (HR 1.27, 95% CI 1.04–1.56;
P= 0.020 per log increase).
When comparing the predictive value of NT-proBNP to
bio-ADM for outcome, NT-proBNP was a stronger predictor
of all-cause mortality (univariable c-index 0.673 for NT-proBNP
vs. 0.636 for bio-ADM), as well as the combined endpoint (uni-
variable c-index 0.652 for NT-proBNP vs. 0.624 for bio-ADM).
Bio-ADM did not improve the net reclassification index on top of
the BIOSTAT-CHF risk model (including NT-proBNP) for both
outcomes (online supplementary Table S5).
Validation of bio-adrenomedullin
The value of bio-ADM in worsening or new-onset HF was sub-
sequently validated in a separate cohort of 1703 HF patients.
Median bio-ADM was 27.3 [18.0–42.1] pg/mL. Baseline charac-
teristics over tertiles of bio-ADM in the validation cohort are
shown in the online supplementary Table S6. The strongest associa-
tions with higher bio-ADM levels in multivariable linear regression
analysis were observed for oedema, higher levels of urea, PENK
and higher heart rate (adjusted r2 = 0.357) (online supplementary
Table S7).
Correlation and network analysis
The heat map (online supplementary Figure S2) illustrates that
bio-ADM levels are most strongly correlated with the clinical
congestion score (Spearman’s rho: 0.37, P< 0.001), the pres-
ence of oedema (Spearman’s rho: 0.34, P< 0.001), and creatinine
Table 2 Comparison of associations with congestion variables between bio-adrenomedullin and N-terminal pro
B-type natriuretic peptide
Bio-ADM NT-proBNP P-value (comparison
bio-ADM vs. NT-proBNP). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Correlation
coefficient (r)
P-value Correlation
coefficient (r)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Oedema (above knee) 0.43 <0.001 0.22 <0.001 <0.001
Orthopnoea 0.24 <0.001 0.17 <0.001 0.036
JVP 0.29 <0.001 0.28 <0.001 0.767
Third heart sound 0.03 0.168 0.05 0.039 0.630
Hepatomegaly 0.16 <0.001 0.12 <0.001 0.157
Rales 0.19 <0.001 0.20 <0.001 0.587
Presented correlations are Spearman’s.
Bio-ADM, biologically active adrenomedullin; JVP, jugular venous pressure; NT-proBNP, N-terminal pro B-type natriuretic peptide.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Bio-adrenomedullin and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or
beta-blocker use after 3months of up-titration in the index cohort
Log bio-ADM ACEi/ARB use P-value Target dose P-value Beta-blocker use P-value Target dose P-value
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Univariable 0.49 (0.42–0.57) <0.001 0.67 (0.57–0.78) <0.001 0.56 (0.47–0.66) <0.001 0.94 (0.79–1.12) 0.500
Multivariablea 0.60 (0.47–0.79) <0.001 0.64 (0.47–0.87) 0.005 0.57 (0.42–0.77) <0.001 0.97 (0.70–1.33) 0.850
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; bio-ADM, biologically active adrenomedullin; CI, confidence interval; OR, odds ratio.
aAdjusted for body mass index, fibroblast growth factor 23, pro-enkephalin, N-terminal pro B-type natriuretic peptide, estimated glomerular filtration rate, age, sex, oedema,
and ACEi/ARB or beta-blocker use at baseline.
Table 4 Cox regression analysis for bio-adrenomedullin and all-cause mortality, and the combined endpoint in the
index cohort
All-cause mortality P-value Multivariablea P-value Combined endpoint Multivariableb P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Univariable HR (95% CI) Univariable P-value HR (95% CI)
HR (95% CI) HR (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Log bio-ADM 1.78 (1.62–1.95) <0.001 1.14 (1.02–1.28) 0.015 1.71 (1.58–1.85) <0.001 1.16 (1.06–1.27) 0.002
Quintile 1 1.0 (Ref) Ref 1.0 (Ref) Ref 1.0 (Ref) Ref 1.0 (Ref) Ref
Quintile 2 1.42 (1.02–1.96) 0.037 1.20 (0.87–1.66) 0.275 1.27 (0.99–1.61) 0.062 1.06 (0.83–1.35) 0.670
Quintile 3 1.69 (1.23–2.31) 0.001 1.11 (0.80–1.53) 0.532 1.56 (1.23–1.97) <0.001 1.11 (0.88–1.41) 0.376
Quintile 4 2.41 (1.79–3.26) <0.001 1.35 (1.00–1.83) 0.056 2.06 (1.64–2.58) <0.001 1.23 (0.98–1.56) 0.076
Quintile 5 3.82 (2.87–5.09) <0.001 1.39 (1.02–1.90) 0.036 3.23 (2.60–4.01) <0.001 1.33 (1.05–1.68) 0.019
bio-ADM, biologically active adrenomedullin; CI, confidence interval; HR, hazard ratio.
aAdjusted for the BIOSTAT-CHF risk model for all-cause mortality (age, log blood urea nitrogen, log N-terminal pro B-type natriuretic peptide, haemoglobin, and beta-blocker
use at baseline).
bAdjusted for the BIOSTAT-CHF risk model for the combined endpoint (age, heart failure hospitalization in previous year, systolic blood pressure, log N-terminal pro B-type
natriuretic peptide, haemoglobin, high-density lipoprotein, sodium, and beta-blocker use at baseline).
(Spearman’s rho: 0.34, P< 0.001). Again, the modified conges-
tion score yielded similar findings. In a hierarchical cluster anal-
ysis (online supplementary Figure S3), bio-ADM clustered with
NT-proBNP and diastolic blood pressure. When for the index
cohort exactly the same variables as in the validation cohort are
entered into a heat map and hierarchical cluster analysis, bio-ADM
clustered with oedema, JVP, hepatomegaly, and the clinical conges-
tion score (online supplementary Figures S4 and S5).
Bio-adrenomedullin and outcomes
In the validation cohort during a median follow-up of 21
[12–33] months, 519 (30.5%) patients died and 715 (42.0%)
experienced the combined endpoint. Cox regression analyses
for (quintiles of) bio-ADM yielded comparable findings to the
index cohort (online supplementary Table S8 and Figure S6). Simi-
lar to the index cohort, when comparing the prognostic value of
bio-ADM to NT-proBNP, NT-proBNP was a stronger predictor
of both endpoints.
Discussion
In patients with new-onset and worsening HF, higher levels
of plasma bio-ADM were strongly associated with more severe HF, .
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.. and signs and symptoms of congestion, and independently associ-
ated with an increased risk of all-cause mortality and HF hospital-
ization. Using network analysis tools, such as hierarchical cluster
analysis, bio-ADM clustered with markers of congestion. Interest-
ingly, patients with higher bio-ADM levels were less likely to receive
target doses of ACEi/ARBs after 3months of up-titration. These
findings were externally validated in a separate cohort of patients
with HF.
Bio-adrenomedullin as a marker
of congestion
Bio-ADM is a vasodilatory peptide hormone that has been shown
to play an essential role in maintaining endothelial barrier function,
and disruption of this regulatory system results in vascular leakage,
and systemic and pulmonary oedema.9 ADM acts both intravas-
cularly as well as in the interstitium. Intravascular ADM acts on
the endothelial cells, improves vascular integrity and decreases vas-
cular permeability, whereas interstitial ADM causes vasodilatation
through its effect on vascular smooth muscle cells.20 Furthermore,
the expression of ADM is stimulated by volume overload, and vice
versa increased plasma ADM reflects excessive fluid overload.11
These elevated levels of bio-ADM in HF are reflective of a coun-
teracting response to volume overload, as an attempt to limit
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Kaplan–Meier curve for all-cause mortality for quintiles of bio-adrenomedullin in the index cohort.
tissue fluid overload by stabilizing the endothelial barrier func-
tion. We recently showed that in patients with acute HF, bio-ADM
at baseline was strongly associated with signs and symptoms of
congestion.7 Interestingly, higher bio-ADM levels after 7 days of
decongestive treatment were associated with significant residual
congestion, this was not observed for NT-proBNP. These findings
suggest that bio-ADM might be a marker of congestion that pro-
vides additional information over NT-proBNP and could possibly
be used to guide decongestive therapy. In this study in patients with
new-onset or worsening HF, slightly lower levels of bio-ADM were
observed compared to the previous study in patients with acute HF
(median bio-ADM 33.8 vs. 44.1 pg/mL). This might confirm that in
patients with more fluid overload, i.e. acute HF, bio-ADM levels are
more elevated. In the present study, however, bio-ADM levels were
increased compared to healthy controls where a median value of
20.7 pg/mL has been described.18
Despite the fact that this study investigated patients with
new-onset or worsening HF with less fluid overload, the strong
association of bio-ADM with congestion is evident. In hierarchi-
cal cluster analysis bio-ADM, as the only biomarker, clustered with
symptoms of congestion. The slight difference in results between
the index and validation cohort might be due to the fact that
patients in the validation cohort were generally less congested
and for instance had significantly lower NT-proBNP levels. Yet,
compared to NT-proBNP, bio-ADM was a stronger predictor of
a clinical congestion score in both cohorts, and for the presence
of oedema in particular. The association of bio-ADM with conges-
tion is further supported by the finding that patients with higher
bio-ADM levels used higher doses of loop diuretics and were more
likely to use loop diuretics after 9months of follow-up. In addition .
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. to an association with congestion markers, bio-ADM also showed
a strong association with FGF23. FGF23 is a phosphaturic hor-
mone that is associated with renin–angiotensin–aldosterone acti-
vation and has been postulated as a regulator of sodium hemostasis
through upregulation of the sodium–chloride co-transporter in the
distal tubule.21 As such the association of bio-ADM with FGF23
might be indicative of congestion and could also suggest less effec-
tive decongestive therapy. Using ROC analyses, the best cut-off for
bio-ADM to assess congestion was 34 pg/mL, which is well above
the median described in healthy volunteers, and if confirmed in
future studies could be used to identify patients with (residual)
congestion. As congestion is notoriously difficult to assess reli-
ably and interobserver variability is considerable, there is a great
need for (bio)markers that aid in reliable assessment of conges-
tion. Our study suggests that bio-ADM is a biomarker that might
have unique characteristics in this aspect, and could have clinical
utility in a broad range of HF patients, i.e. from new-onset to acute
HF. Future studies, preferentially using more objective measures to
assess congestion, such as echography, in addition to physical exam-
ination will have to show whether bio-ADM does indeed provide
additional information on top of this. Interestingly, patients with
higher bio-ADM levels were less well up-titrated with ACEi or ARB,
which may be due to possible residual congestion and diuretic use,
or more severe HF, hypotension and haemodynamic intolerance
of these drugs. The association of bio-ADM with ACEi or ARB
up-titration after 3months was however independent of several
markers of HF severity, such as NT-proBNP, and baseline use of
ACEi or ARB.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Bio-adrenomedullin as a marker
for clinical outcome
In the present study, we found that higher bio-ADM levels were
independently associated with poorer clinical outcome in patients
with new-onset and worsening HF. This finding confirms previ-
ous studies that reported added prognostic value of bio-ADM
for shorter-term outcomes.7,8,22 We also found that higher levels
of bio-ADM were independently associated with an increased risk
of the combined endpoint, which includes both all-cause mortality
and HF hospitalization. The strong association between higher
levels of bio-ADM and a higher risk of hospital (re)admission
is of particular interest, since the main cause of HF admis-
sions for worsening HF is related to congestion. The addition
of bio-ADM to a model that included NT-proBNP did however
not improve the net reclassification index. Therefore, the main
value of bio-ADM might not be in predicting outcome, yet in
its role as a congestion marker. As such it would have novel
and additive value, compared to more established markers such
as troponin or NT-proBNP. Taken together, our findings suggest
that bio-ADM might be used to guide (decongestive) therapy,
and possibly assess low risk of (re)hospitalization at discharge.
Further studies in which bio-ADM is assessed at multiple time
points during HF hospitalization might be able to shed more light
on this.
Adrenomedullin as a therapeutic target
Finally, bio-ADM might be a modifiable risk factor, for instance
by administering adrecizumab, a humanized, monoclonal
non-neutralizing antibody against the N-terminus of ADM, that
increases plasma concentrations of bio-ADM in a dose-dependent
manner.23 In animal models of systemic inflammation and septic
shock, adrecizumab has shown promising results by improving
haemodynamics and renal function.23,24 In HF, administration of
adrecizumab might result in improved vascular integrity with
consequent improvement of tissue congestion and possibly
outcomes.20 Of note, pharmacologic inhibition of neprilysin
increased the plasma levels and potentiated the natriuretic and
diuretic responses of ADM, when exogenously applied in a dog
model.25 On that background it could be hypothesized that the
beneficial effects of sacubitril/valsartan in HF might be partly
explained by this mechanism.
Bio- and pro-adrenomedullin
In this study, a relatively novel ADM assay was used that
assesses bio-ADM. Until recently ADM activity was measured
using a biomarker that assessed an ADM precursor peptide
(pro-ADM), which is in contrast to bio-ADM.17 In this study,
pro-ADM explained merely 30% of the variance in bio-ADM
levels. Hierarchical clustering showed that pro-ADM did not
cluster with bio-ADM or with congestion markers, yet with
FGF23 and GDF15. This suggests that bio-ADM and pro-ADM
could provide insight into different underlying pathophysiological
processes. ..
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.. Strengths and limitations
This is the first study to assess the value of bio-ADM in patients
with new-onset and worsening HF. Strengths of this study are
the number of patients enrolled in this cohort, the validation in a
separate cohort, as well as the extensive (bio)marker data avail-
able. Limitations of this study are the retrospective, observational
design, the assessment of bio-ADM at one time point, and the lack
of information regarding decongestion or decongestive treatment.
Also, the congestion score used in this study is a modified score
from the previously published congestion scores due to differences
in recording of congestion variables.26,27 Furthermore, bio-ADM
was particularly strongly associated with easier to assess variables
of congestion, i.e. oedema and orthopnoea; therefore, more objec-
tive markers to assess congestion, such as ultrasound, invasive
haemodynamic measurements, or plasma volume should be stud-
ied in subsequent studies. These were unfortunately not available
in this dataset. However, at the moment there is no gold stan-
dard for the assessment of congestion in HF.28 Based on this study,
only associations are described and causality cannot be proven.
Although bio-ADMwas associated with clinical outcome in univari-
able models, there was no strong additive value on top of existing
markers of clinical outcome.
Future perspectives
Future studies should assess the value of bio-ADM to guide (decon-
gestive) treatment and might improve assessment of congestion
in order to reliably establish euvolaemia. Also, therapies aimed
at increasing ADM levels, for instance by administration of adre-
cizumab or neprilysin inhibitors, could be considered in order
to improve outcomes.
Conclusions
Elevated plasma bio-ADM levels in patients with new-onset
and worsening HF are associated with typical signs and symptoms
of congestion and with an increased risk of mortality and HF
hospitalization. Bio-ADM might therefore be useful to guide
decongestive therapy or might become a target for therapy.
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